Human insulin market seen reaching $26.9 billion by 2031

By AI, Created 1:25 PM UTC, May 21, 2026, /AGP/ – Persistence Market Research says the global human insulin market will grow from $19.8 billion in 2024 to $26.9 billion by 2031, driven by rising diabetes cases, broader diagnosis and steadier access to therapy. North America leads now, while Asia Pacific is poised for faster growth as demand for affordable diabetes treatment expands.

Why it matters: - Human insulin remains a core therapy for people who need blood sugar control, especially in type 1 diabetes and advanced type 2 diabetes. - The market’s expected growth signals continued demand for affordable diabetes treatment as diagnosis rates rise worldwide. - The projected expansion could shape access, pricing and delivery systems across hospitals, pharmacies and homecare settings.

What happened: - Persistence Market Research estimates the global human insulin market will rise from US$ 19.8 billion in 2024 to US$ 26.9 billion by 2031. - The forecast implies a 5.1% compound annual growth rate from 2024 to 2031. - The report points to rising diabetes prevalence, improved access to insulin therapies and steady demand for long-term diabetes care. - North America holds a leading market position. - Asia Pacific is expected to post strong growth.

The details: - Human insulin products for routine diabetes management are expected to remain the largest segment because of broad prescription use and ongoing patient dependence. - Short-acting human insulin is used for mealtime glucose control. - Intermediate-acting insulin supports basal insulin needs. - Premixed insulin serves patients that need simplified dosing and consistent glycemic control. - Hospitals, specialty clinics, retail pharmacies and homecare settings make up the main end-user base. - Hospitals support diagnosis, prescription and emergency diabetes care. - Retail pharmacies remain a key channel for regular insulin access. - Homecare use is increasing as more patients self-administer and monitor glucose routinely. - North America benefits from advanced healthcare infrastructure, high diabetes awareness, strong reimbursement and wide availability of insulin delivery systems. - Asia Pacific growth is supported by rising diabetes cases, better healthcare access, expanding urban populations and lifestyle-related diabetes risk. - The report says rising sedentary behavior, obesity, aging populations and dietary changes are increasing diabetes incidence. - Better screening, awareness campaigns and healthcare programs are improving early diagnosis and treatment adoption. - High treatment costs can still limit access in some regions, especially for uninsured or underinsured patients. - Patient adherence remains a challenge because insulin therapy requires regular dosing, monitoring and lifestyle discipline. - Fear of injections, dosing errors and limited patient education can reduce consistency. - Emerging economies, government diabetes programs and stronger pharmacy networks create room for expansion. - Improved insulin pens, education platforms and glucose-monitoring integration could support adherence and long-term growth. - Key companies in the market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon Limited, Wockhardt Ltd., Tonghua Dongbao Pharmaceutical Co., Ltd., Julphar, Pfizer Inc., Merck & Co., Inc. and Boehringer Ingelheim International GmbH. - The report offers a free sample and customization option through Persistence Market Research. - The company also offers full report access through its checkout page. - Relevant links include the free sample, report customization and the full report.

Between the lines: - The forecast suggests human insulin is still positioned as a dependable, lower-cost option in diabetes care even as treatment tools evolve. - The strongest growth may come from markets where access is improving faster than incomes, putting pressure on affordability and distribution. - North America’s lead reflects not just disease burden, but also stronger reimbursement and delivery infrastructure.

What’s next: - Market growth will likely track diabetes screening rates, access to therapies and the pace of adoption for simpler delivery tools. - Emerging markets may become a bigger revenue driver if pharmacy access and public health programs continue to expand. - Companies competing in the market will likely focus on affordability, adherence support and patient-friendly delivery systems.